Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

CD19 CAR T Cells Following Autologous Transplantation in Poor Risk Relapsed and Refractory B cell non-Hodgkin Lymphoma.

Sauter CS, Senechal B, Rivière I, Ni A, Bernal Y, Wang X, Purdon T, Hall M, Singh AN, Szenes VZ, Yoo S, Dogan A, Wang Y, Moskowitz CH, Giralt S, Matasar MJ, Perales MA, Curran KJ, Park J, Sadelain M, Brentjens RJ.

Blood. 2019 Jul 1. pii: blood.2018883421. doi: 10.1182/blood.2018883421. [Epub ahead of print]

PMID:
31262783
2.

BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy.

Smith EL, Mailankody S, Staehr M, Wang X, Senechal B, Purdon TJ, Daniyan AF, Geyer MB, Goldberg AD, Mead E, Santomasso BD, Landa J, Rimner A, Riviere I, Landgren O, Brentjens RJ.

Cancer Immunol Res. 2019 Jul;7(7):1047-1053. doi: 10.1158/2326-6066.CIR-18-0551. Epub 2019 May 21.

PMID:
31113804
3.

Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.

Geyer MB, Rivière I, Sénéchal B, Wang X, Wang Y, Purdon TJ, Hsu M, Devlin SM, Palomba ML, Halton E, Bernal Y, van Leeuwen DG, Sadelain M, Park JH, Brentjens RJ.

JCI Insight. 2019 Apr 2;5. pii: 122627. doi: 10.1172/jci.insight.122627.

4.

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.

Smith EL, Harrington K, Staehr M, Masakayan R, Jones J, Long TJ, Ng KY, Ghoddusi M, Purdon TJ, Wang X, Do T, Pham MT, Brown JM, De Larrea CF, Olson E, Peguero E, Wang P, Liu H, Xu Y, Garrett-Thomson SC, Almo SC, Wendel HG, Riviere I, Liu C, Sather B, Brentjens RJ.

Sci Transl Med. 2019 Mar 27;11(485). pii: eaau7746. doi: 10.1126/scitranslmed.aau7746.

PMID:
30918115
5.

CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.

Kuhn NF, Purdon TJ, van Leeuwen DG, Lopez AV, Curran KJ, Daniyan AF, Brentjens RJ.

Cancer Cell. 2019 Mar 18;35(3):473-488.e6. doi: 10.1016/j.ccell.2019.02.006.

PMID:
30889381
6.

CARs of the future.

Daniyan AF, Brentjens RJ.

Am J Hematol. 2019 May;94(S1):S55-S58. doi: 10.1002/ajh.25416. Epub 2019 Feb 25. Review.

PMID:
30680777
7.

Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia.

Jin CH, Xia J, Rafiq S, Huang X, Hu Z, Zhou X, Brentjens RJ, Yang YG.

EBioMedicine. 2019 Jan;39:173-181. doi: 10.1016/j.ebiom.2018.12.013. Epub 2018 Dec 20.

8.

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.

Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR.

J Immunother Cancer. 2018 Dec 4;6(1):137. doi: 10.1186/s40425-018-0460-5. Review.

9.

Tumors evading CARs-the chase is on.

Rafiq S, Brentjens RJ.

Nat Med. 2018 Oct;24(10):1492-1493. doi: 10.1038/s41591-018-0212-6. No abstract available.

PMID:
30297897
10.

Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience.

Cornetta K, Duffy L, Feldman SA, Mackall CL, Davila ML, Curran KJ, Junghans RP, Tang JY, Kochenderfer JN, O'Cearbhaill R, Archer G, Kiem HP, Shah NN, Delbrook C, Kaplan R, Brentjens RJ, Rivière I, Sadelain M, Rosenberg SA.

Mol Ther Methods Clin Dev. 2018 Aug 17;10:371-378. doi: 10.1016/j.omtm.2018.08.006. eCollection 2018 Sep 21.

11.

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo.

Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, Yan S, Xiang J, Ma X, Seshan VE, Hendrickson RC, Liu C, Brentjens RJ.

Nat Biotechnol. 2018 Oct;36(9):847-856. doi: 10.1038/nbt.4195. Epub 2018 Aug 13.

12.

Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.

Geyer MB, Rivière I, Sénéchal B, Wang X, Wang Y, Purdon TJ, Hsu M, Devlin SM, Halton E, Lamanna N, Rademaker J, Sadelain M, Brentjens RJ, Park JH.

Mol Ther. 2018 Aug 1;26(8):1896-1905. doi: 10.1016/j.ymthe.2018.05.018. Epub 2018 Jun 15.

PMID:
29910179
13.

Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.

Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, Cross JR, Liu H, Vachha B, Chen X, DeAngelis LM, Li D, Bernal Y, Gonen M, Wendel HG, Sadelain M, Brentjens RJ.

Cancer Discov. 2018 Aug;8(8):958-971. doi: 10.1158/2159-8290.CD-17-1319. Epub 2018 Jun 7.

PMID:
29880584
14.

Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System.

Avanzi MP, Yeku O, Li X, Wijewarnasuriya DP, van Leeuwen DG, Cheung K, Park H, Purdon TJ, Daniyan AF, Spitzer MH, Brentjens RJ.

Cell Rep. 2018 May 15;23(7):2130-2141. doi: 10.1016/j.celrep.2018.04.051.

15.

Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector.

Smith EL, Staehr M, Masakayan R, Tatake IJ, Purdon TJ, Wang X, Wang P, Liu H, Xu Y, Garrett-Thomson SC, Almo SC, Riviere I, Liu C, Brentjens RJ.

Mol Ther. 2018 Jun 6;26(6):1447-1456. doi: 10.1016/j.ymthe.2018.03.016. Epub 2018 Mar 28.

16.

Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center.

Perica K, Curran KJ, Brentjens RJ, Giralt SA.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1135-1141. doi: 10.1016/j.bbmt.2018.02.018. Epub 2018 Mar 1. Review.

17.

Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells.

Park JH, Romero FA, Taur Y, Sadelain M, Brentjens RJ, Hohl TM, Seo SK.

Clin Infect Dis. 2018 Aug 1;67(4):533-540. doi: 10.1093/cid/ciy152.

PMID:
29481659
18.

Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.

Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini M, Rosenblat T, Jurcic JG, Brentjens RJ, Arcila ME, Rampal R, Park JH, Douer D, Katz L, Sarlis N, Tallman MS, Scheinberg DA.

Blood Adv. 2018 Feb 13;2(3):224-234. doi: 10.1182/bloodadvances.2017014175.

19.

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.

Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ, Sadelain M.

N Engl J Med. 2018 Feb 1;378(5):449-459. doi: 10.1056/NEJMoa1709919.

20.

Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma.

Avanzi MP, Brentjens RJ.

J Natl Compr Canc Netw. 2017 Nov;15(11):1429-1437. doi: 10.6004/jnccn.2017.7045. Review.

PMID:
29118234
21.

CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

Ghosh A, Mailankody S, Giralt SA, Landgren CO, Smith EL, Brentjens RJ.

Leuk Lymphoma. 2018 Sep;59(9):2056-2067. doi: 10.1080/10428194.2017.1393668. Epub 2017 Nov 6. Review.

PMID:
29105517
22.

Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.

Geyer MB, Manjunath SH, Evans AG, Park JH, Davila ML, Cutler CS, Wang X, Wang Y, Senechal B, Rivière I, Sadelain M, Liesveld JL, Brentjens RJ.

Leuk Lymphoma. 2018 Jul;59(7):1717-1721. doi: 10.1080/10428194.2017.1390237. Epub 2017 Oct 18. No abstract available.

23.

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment.

Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ.

Sci Rep. 2017 Sep 5;7(1):10541. doi: 10.1038/s41598-017-10940-8.

24.

Adoptive T-Cell Therapy for Solid Tumors.

Yeku O, Li X, Brentjens RJ.

Am Soc Clin Oncol Educ Book. 2017;37:193-204. doi: 10.14694/EDBK_180328.

25.

Immunotherapy: Hiding in plain sight: immune escape in the era of targeted T-cell-based immunotherapies.

Daniyan AF, Brentjens RJ.

Nat Rev Clin Oncol. 2017 Jun;14(6):333-334. doi: 10.1038/nrclinonc.2017.49. Epub 2017 Apr 11. Review. No abstract available.

26.

Development of CAR T cells designed to improve antitumor efficacy and safety.

Jaspers JE, Brentjens RJ.

Pharmacol Ther. 2017 Oct;178:83-91. doi: 10.1016/j.pharmthera.2017.03.012. Epub 2017 Mar 22. Review.

27.
28.

Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.

Rafiq S, Purdon TJ, Daniyan AF, Koneru M, Dao T, Liu C, Scheinberg DA, Brentjens RJ.

Leukemia. 2017 Aug;31(8):1788-1797. doi: 10.1038/leu.2016.373. Epub 2016 Dec 7.

29.

At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.

Daniyan AF, Brentjens RJ.

J Leukoc Biol. 2016 Dec;100(6):1255-1264. Epub 2016 Oct 27. Review.

30.

Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.

Boice M, Salloum D, Mourcin F, Sanghvi V, Amin R, Oricchio E, Jiang M, Mottok A, Denis-Lagache N, Ciriello G, Tam W, Teruya-Feldstein J, de Stanchina E, Chan WC, Malek SN, Ennishi D, Brentjens RJ, Gascoyne RD, Cogné M, Tarte K, Wendel HG.

Cell. 2016 Oct 6;167(2):405-418.e13. doi: 10.1016/j.cell.2016.08.032. Epub 2016 Sep 29.

31.

Toxicity and management in CAR T-cell therapy.

Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ.

Mol Ther Oncolytics. 2016 Apr 20;3:16011. doi: 10.1038/mto.2016.11. eCollection 2016. Review.

32.

Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.

Geyer MB, Brentjens RJ.

Cytotherapy. 2016 Nov;18(11):1393-1409. doi: 10.1016/j.jcyt.2016.07.003. Epub 2016 Aug 31. Review.

33.

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.

Park JH, Geyer MB, Brentjens RJ.

Blood. 2016 Jun 30;127(26):3312-20. doi: 10.1182/blood-2016-02-629063. Epub 2016 May 20. Review.

34.

Medical management of side effects related to CAR T cell therapy in hematologic malignancies.

Namuduri M, Brentjens RJ.

Expert Rev Hematol. 2016 Jun;9(6):511-3. doi: 10.1080/17474086.2016.1183479. Epub 2016 May 19. No abstract available.

35.

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.

Khalil DN, Smith EL, Brentjens RJ, Wolchok JD.

Nat Rev Clin Oncol. 2016 Jun;13(6):394. doi: 10.1038/nrclinonc.2016.65. Epub 2016 Apr 26. No abstract available.

36.

Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy.

Yeku OO, Brentjens RJ.

Biochem Soc Trans. 2016 Apr 15;44(2):412-8. doi: 10.1042/BST20150291. Review.

37.

Are chimeric antigen receptor T cells ready for prime time?

Brentjens RJ.

Clin Adv Hematol Oncol. 2016 Jan;14(1):17-9. No abstract available.

38.

Driving CAR T-cells forward.

Jackson HJ, Rafiq S, Brentjens RJ.

Nat Rev Clin Oncol. 2016 Jun;13(6):370-83. doi: 10.1038/nrclinonc.2016.36. Epub 2016 Mar 22. Review.

39.

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.

Khalil DN, Smith EL, Brentjens RJ, Wolchok JD.

Nat Rev Clin Oncol. 2016 May;13(5):273-90. doi: 10.1038/nrclinonc.2016.25. Epub 2016 Mar 15. Review. Erratum in: Nat Rev Clin Oncol. 2016 Jun;13(6):394.

40.

Overcoming Antigen Escape with CAR T-cell Therapy.

Jackson HJ, Brentjens RJ.

Cancer Discov. 2015 Dec;5(12):1238-40. doi: 10.1158/2159-8290.CD-15-1275.

41.

Novel immunotherapies in lymphoid malignancies.

Batlevi CL, Matsuki E, Brentjens RJ, Younes A.

Nat Rev Clin Oncol. 2016 Jan;13(1):25-40. doi: 10.1038/nrclinonc.2015.187. Epub 2015 Nov 3. Review.

42.
43.

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.

Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ.

Oncoimmunology. 2015 Jan 23;4(3):e994446. eCollection 2015 Mar.

44.

Chimeric antigen receptor T cells for cancer immunotherapy.

Curran KJ, Brentjens RJ.

J Clin Oncol. 2015 May 20;33(15):1703-6. doi: 10.1200/JCO.2014.60.3449. Epub 2015 Apr 20. No abstract available.

PMID:
25897155
45.

A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.

Koneru M, O'Cearbhaill R, Pendharkar S, Spriggs DR, Brentjens RJ.

J Transl Med. 2015 Mar 28;13:102. doi: 10.1186/s12967-015-0460-x.

46.

Are all chimeric antigen receptors created equal?

Park JH, Brentjens RJ.

J Clin Oncol. 2015 Feb 20;33(6):651-3. doi: 10.1200/JCO.2014.57.5472. Epub 2015 Jan 20. No abstract available.

PMID:
25605860
47.

Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.

Curran KJ, Seinstra BA, Nikhamin Y, Yeh R, Usachenko Y, van Leeuwen DG, Purdon T, Pegram HJ, Brentjens RJ.

Mol Ther. 2015 Apr;23(4):769-78. doi: 10.1038/mt.2015.4. Epub 2015 Jan 13.

48.

T-cell immunotherapy: looking forward.

Corrigan-Curay J, Kiem HP, Baltimore D, O'Reilly M, Brentjens RJ, Cooper L, Forman S, Gottschalk S, Greenberg P, Junghans R, Heslop H, Jensen M, Mackall C, June C, Press O, Powell D, Ribas A, Rosenberg S, Sadelain M, Till B, Patterson AP, Jambou RC, Rosenthal E, Gargiulo L, Montgomery M, Kohn DB.

Mol Ther. 2014 Sep;22(9):1564-74. doi: 10.1038/mt.2014.148. No abstract available.

49.

IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.

Pegram HJ, Purdon TJ, van Leeuwen DG, Curran KJ, Giralt SA, Barker JN, Brentjens RJ.

Leukemia. 2015 Feb;29(2):415-22. doi: 10.1038/leu.2014.215. Epub 2014 Jul 9.

50.

Acute myeloid leukemia arising from a donor derived premalignant hematopoietic clone: A possible mechanism for the origin of leukemia in donor cells.

Dickson MA, Papadopoulos EB, Hedvat CV, Jhanwar SC, Brentjens RJ.

Leuk Res Rep. 2014 May 20;3(2):38-41. doi: 10.1016/j.lrr.2014.04.001. eCollection 2014.

Supplemental Content

Loading ...
Support Center